Aerie Pharma submits prior approval supplement to FDA to allow production of Rocklatan®
Aerie Pharmaceuticals announced the submission of a prior approval supplement to the FDA. If approved, the PAS will permit production of Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for sale in the U.S. in Aerie’s new manufacturing plant in Athlone, Ireland. September 19, 2019